» Articles » PMID: 24378809

Fascin1 Expression in High-grade Serous Ovarian Carcinoma is a Prognostic Marker and Knockdown of Fascin1 Suppresses the Proliferation of Ovarian Cancer Cells

Overview
Journal Int J Oncol
Specialty Oncology
Date 2014 Jan 1
PMID 24378809
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Fascin1 (FSCN1) involved in cell motility and filopodia assembly plays important roles in biological processes such as cancer invasion and metastasis of multiple epithelial tumors. High-grade serous ovarian carcinoma (HGSOC) is aggressive and metastatic by acquiring an invasive phenotype and this step requires remodeling of the actin cytoskeleton. Thus, the present study aimed to investigate the expression of fascin1 in HGSOC tissues as well as its clinical significance such as prognostic predictors and its utility of therapeutic target. Fascin1 and β-catenin were evaluated using immunohistochemistry on a tissue microarray of 79 HGSOC. Small interfering RNA (siRNA) approach was used to knock down fascin1 expression in ovarian cancer cell lines to determine whether fascin1 contributes to tumor cell proliferation, migration and invasion. Fascin1 expression levels were determined by western blot analysis after siRNA transfection using two human ovarian cancer cell lines (SKOV3 and OVCAR3). Fascin1 overexpression was significantly correlated with lymph node involvement, distance metastasis and high International Federation of Gynecology and Obstetrics (FIGO) stage (III/IV) (P<0.05). A Kaplan-Meier analysis showed that the fascin1 expression group was significantly associated with poor overall survival (P=0.010). We showed that inactivation of fascin1 by siRNA transfection led to a drop in cell viability, and significantly decreased tumor cell proliferation, migration and invasiveness compared to untransfected cells. We found that fascin1 expression is a potential poor marker of prognosis for patients with HGSOC and knockdown of fascin1 suppresses ovarian cancer cell proliferation and migration, this could be applied for therapeutic targets in ovarian cancer treatment.

Citing Articles

The association of FSCN1 (rs852479, rs1640233) and HOTAIR (rs920778) polymorphisms with the risk of breast cancer in Egyptian women.

Galal E, Abdelhakam D, Ahmed L, Elhusseny Y, Sayed S, Eltaweel N Mol Biol Rep. 2024; 51(1):495.

PMID: 38587571 PMC: 11001669. DOI: 10.1007/s11033-024-09459-9.


Fascin actin-bundling protein 1 in human cancer: promising biomarker or therapeutic target?.

Liu H, Zhang Y, Li L, Cao J, Guo Y, Wu Y Mol Ther Oncolytics. 2021; 20:240-264.

PMID: 33614909 PMC: 7873579. DOI: 10.1016/j.omto.2020.12.014.


Identification of the fatty acid synthase interaction network via iTRAQ-based proteomics indicates the potential molecular mechanisms of liver cancer metastasis.

Huang J, Tang Y, Zou X, Lu Y, She S, Zhang W Cancer Cell Int. 2020; 20:332.

PMID: 32699531 PMC: 7372886. DOI: 10.1186/s12935-020-01409-2.


FSCN1 is an effective marker of poor prognosis and a potential therapeutic target in human tongue squamous cell carcinoma.

Chen Y, Tian T, Li Z, Wang C, Deng R, Deng W Cell Death Dis. 2019; 10(5):356.

PMID: 31043585 PMC: 6494834. DOI: 10.1038/s41419-019-1574-5.


Long non-coding RNA ZEB1-AS1 regulates miR-200b/FSCN1 signaling and enhances migration and invasion induced by TGF-β1 in bladder cancer cells.

Gao R, Zhang N, Yang J, Zhu Y, Zhang Z, Wang J J Exp Clin Cancer Res. 2019; 38(1):111.

PMID: 30823924 PMC: 6397446. DOI: 10.1186/s13046-019-1102-6.


References
1.
Tao Y, Edwards R, Tubb B, Wang S, Bryan J, McCrea P . beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex. J Cell Biol. 1996; 134(5):1271-81. PMC: 2120989. DOI: 10.1083/jcb.134.5.1271. View

2.
Kabukcuoglu S, Ozalp S, Oner U, Bildirici K, Yalcin O, Oge T . Actin bundling protein fascin expression in ovarian neoplasms: comparison of histopathologic features of tumors obtained by the first and secondary cytoreduction surgeries. Eur J Gynaecol Oncol. 2006; 27(2):123-8. View

3.
Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

4.
Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A . beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol. 1999; 155(2):527-36. PMC: 1866843. DOI: 10.1016/s0002-9440(10)65148-6. View

5.
Li A, Dawson J, Forero-Vargas M, Spence H, Yu X, Konig I . The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol. 2010; 20(4):339-45. PMC: 3163294. DOI: 10.1016/j.cub.2009.12.035. View